Browsing
     by title


0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

or enter first few letters:   
OK
Full Text
Peer Reviewed
See detailThe lymphatic ring assay: a 3D-culture model of lymphangiogenesis.
Bruyere, Françoise ULg; Melen-Lamalle, Laurence ULg; Berndt, Sarah ULg et al

in Nature Protocols (2008)

Lymphangiogenesis, the formation of new lymphatic vessels, is associated to numerous pathologies1 and understanding the molecular and cellular basis of this complex process is essential for the ... [more ▼]

Lymphangiogenesis, the formation of new lymphatic vessels, is associated to numerous pathologies1 and understanding the molecular and cellular basis of this complex process is essential for the development of novel therapeutic strategies. Studies on lymphangiogenesis have been hampered by difficulties in culturing lymphatic capillaries as three-dimensional (3D) structures in vitro that mimic the in vivo features of lymphatic vessels and lymphangiogenesis. The lymphatic ring assay described here phenocopies the different steps of lymphangiogenesis, including the spreading from a preexisting vessel, cell proliferation, migration and differentiation into capillaries. It consists on the adaptation of the aortic ring assay that has proved to be useful to investigate the molecular basis of angiogenesis2-4. The lymphatic ring model is an ideal assay for testing the activity of lymphangiogenic agonists or antagonists. The absence of inflammatory cells allows a simple interpretation of results and the determination of direct effects of compounds on lymphatic endothelial cell properties. Another advantage of the lymphatic ring assay is that cell outgrowing are primary cells which have not been modified by repeated passages or immortalization. This culture model bridges the gap between in vitro and in vivo studies and allows genetic analysis by using thoracic ducts from genetically modified mice. [less ▲]

Detailed reference viewed: 202 (29 ULg)
See detaillymphatic ring assay: a new in vitro model of lymphangiogenesis
Bruyère, F; Melen, L; Blacher, Silvia ULg et al

Poster (2006)

Detailed reference viewed: 9 (2 ULg)
See detailThe lymphatic ring assay: a new in vitro model of lymphangiogenesis
Bruyère, F; Melen, L; Blacher, Silvia ULg et al

Poster (2006)

Detailed reference viewed: 9 (3 ULg)
Full Text
Peer Reviewed
See detailThe lymphatic ring assay: a new in vitro model of lymphangiogenesis
Bruyère, F; Melen-Lamalle, L; Blacher, Silvia ULg et al

in Acta Clinica Belgica (2008), 63

Detailed reference viewed: 9 (5 ULg)
See detailThe lymphatic ring assay: a new in vitro model of lymphangiogenesis
Bruyère, F; Melen, L; Blacher, Silvia ULg et al

Poster (2007)

Detailed reference viewed: 8 (3 ULg)
See detailThe lymphatic ring assay: a new in vitro model of lymphangiogenesis
Bruyère, F; Melen, L; Blacher, Silvia ULg et al

Conference (2006)

Detailed reference viewed: 10 (2 ULg)
Peer Reviewed
See detailLymphocyte activation and the family of NF-kappa B transcription factor complexes.
Bours, Vincent ULg; Franzoso, G.; Brown, K. et al

in Current Topics in Microbiology and Immunology (1992), 182

Detailed reference viewed: 6 (2 ULg)
Full Text
See detailLymphocyte apoptosis assay: an interlaboraty comparison
Mirimanoff; Bodis; Bernier et al

Scientific conference (1999, March 04)

Detailed reference viewed: 15 (0 ULg)
Full Text
Peer Reviewed
See detailLymphocyte Kinetics: The Interpretation Of Labelling Data
Asquith, B.; Debacq, C.; Macallan, Dc. et al

in Trends In Immunology (2002), 23(12),

Detailed reference viewed: 12 (1 ULg)
Peer Reviewed
See detailLymphocyte Lifespan in Murine Retrovirus-Induced Immunodeficiency
Moutschen, Michel ULg; Colombi, S.; Deprez, Manuel ULg et al

in Advances in Experimental Medicine and Biology (1994), 355

Detailed reference viewed: 18 (3 ULg)
Full Text
Peer Reviewed
See detailLymphocytic colitis: a distinct clinical entity? A clinicopathological confrontation of lymphocytic and collagenous colitis.
Baert, F.; Wouters, K.; D'Haens, G. et al

in Gut (1999), 45(3), 375-81

BACKGROUND AND AIMS: It is not known whether lymphocytic colitis and collagenous colitis represent different clinical entities or constitute part of a spectrum of disease. METHODS: Detailed clinical ... [more ▼]

BACKGROUND AND AIMS: It is not known whether lymphocytic colitis and collagenous colitis represent different clinical entities or constitute part of a spectrum of disease. METHODS: Detailed clinical features and histological findings were compared in a large series of patients with confirmed lymphocytic and collagenous colitis. RESULTS: Histological diagnosis was confirmed in 96 patients with collagenous colitis and 80 with lymphocytic colitis. Twenty eight per cent of patients with collagenous colitis and 26% of patients with lymphocytic colitis had overlapping but less pronounced histological features. Both groups were equal in terms of age, use of aspirin and non-steroidal anti-inflammatory drugs, associated autoimmune conditions, arthritis, diarrhoea, and abdominal pain. The male:female ratio was 27:73 for collagenous colitis and 45:55 for lymphocytic colitis (p=0.013). Twenty five per cent of patients with collagenous colitis compared with 14% of patients with lymphocytic colitis were active smokers; only 8.3% of patients with collagenous colitis had stopped smoking compared with 23% of patients with lymphocytic colitis (p=0.013). Drug induced disease was suspected for ticlopidine (two collagenous colitis, four lymphocytic colitis) and flutamide (four lymphocytic colitis). Mean duration of symptoms before diagnosis was two months for lymphocytic colitis and four months for collagenous colitis. Overall prognosis was generally mild; 84% of patients with lymphocytic colitis and 74% of patients with collagenous colitis reported resolution or significant improvement (p=0.033). CONCLUSIONS: Collagenous and lymphocytic colitis are similar but not identical. Patients with lymphocytic colitis present somewhat earlier and are less likely to be active smokers. Symptoms are milder and more likely to disappear in lymphocytic colitis. Ticlopidine and flutamide should be added to the list of drugs inducing colitis. [less ▲]

Detailed reference viewed: 31 (1 ULg)
Peer Reviewed
See detailLymphoid cell apoptosis induced by trophoblastic cells: a model of active foeto-placental tolerance
Coumans, Bernard ULg; Thellin, Olivier ULg; Zorzi, Willy ULg et al

in Journal of Immunological Methods (1999), 224(1-2), 185-196

To test the hypothesis that CD95-L (Fas-L) present on trophoblastic cells plays a part in establishing foeto-placental tolerance by inducing apoptosis of immune defence cells, we cocultured trophoblasts ... [more ▼]

To test the hypothesis that CD95-L (Fas-L) present on trophoblastic cells plays a part in establishing foeto-placental tolerance by inducing apoptosis of immune defence cells, we cocultured trophoblasts with lymphoid cells and scored the frequency of cell death in these cultures. We prepared human trophoblastic cells from term placentas removed by C-section and placed them in culture for 48 h before introducing the lymphoid cells. We added Jurkat cells, a CD3 + lymphoid cell line, or purified T cells from human blood to the cultured trophoblasts and monitored apoptosis by electron microscopy and flow cytometry after TUNEL or annexin V labelling. The frequency of cell death in the CD3 + cell population was higher when the lymphoid cells were cocultured with trophoblastic cells than when they were cultured alone. This frequency increased with time but was reduced when anti-CD95-L antibodies were added to the culture medium. Cell death was less frequent in the lymphoid cell population when trophoblasts were replaced with human fibroblasts not expressing CD95-L. (C) 1999 Elsevier Science B.V. All rights reserved. [less ▲]

Detailed reference viewed: 33 (4 ULg)
Full Text
See detailThe lymphomas. Nuclear Medicine
Jerusalem, Guy ULg; Hustinx, Roland ULg

in Canellos, George P.; Lister, Andrew T.; Young, Brian (Eds.) The lymphomas. (2006)

Detailed reference viewed: 25 (2 ULg)
Full Text
Peer Reviewed
See detailLymphome centrocytique-centroblastique ou est-il bon, est-il méchant ?
Fillet, Georges ULg; Desoignies, J.; Jardon-Jeghers, C. et al

in Revue Médicale de Liège (1982)

Detailed reference viewed: 121 (1 ULg)
Full Text
Peer Reviewed
See detailLymphome du manteau : prise en charge 2011
Bonnet, Christophe ULg; CAERS, Jo ULg; DE PRIJCK, Bernard ULg et al

in Revue Médicale Suisse (2011), 7

Le lymphome du manteau (LM) représente 6% des lymphomes non hodgkiniens (LNH). Le diagnostic repose sur l'immunophénotypage et la démonstration de la présence de la location entre les chromosomes 11 et 14 ... [more ▼]

Le lymphome du manteau (LM) représente 6% des lymphomes non hodgkiniens (LNH). Le diagnostic repose sur l'immunophénotypage et la démonstration de la présence de la location entre les chromosomes 11 et 14, avec surexpression de la cycline D1. Le traitement de première ligne du sujet jeune associe trois cures de R-CHOP21 alternées avec trois cures de R-DHAP21, suivies d'une autogreffe conditionnée par irradiation corporelle totale, cyclophosphamide et aracytine. Le sujet de plus de 65 ans peut bénéficier de huit cures de R-CHOP21. L'intérêt du traitement de maintenance est en cours d'évaluation. L'allogreffe de cellules souches hématopoïétiques offre une chance de guérison aux patients en rechute en bon état général. Les traitements ciblés permettront une amélioration du pronostic de cette maladie. [less ▲]

Detailed reference viewed: 55 (4 ULg)
Full Text
Peer Reviewed
See detailLe lymphome malin primitif du rachis: aspects cliniques et progrès thérapeutiques
Vanderick, JEAN ULg; Toussaint; Massager et al

in Acta Orthopaedica Belgica (1999), 65(1), 23-32

Malignant lymphomas are occasionally encountered in the spine, where they are usually secondary deposits. The authors report the case of a primary non-Hodgkin lymphoma of the L1 vertebra in whom surgical ... [more ▼]

Malignant lymphomas are occasionally encountered in the spine, where they are usually secondary deposits. The authors report the case of a primary non-Hodgkin lymphoma of the L1 vertebra in whom surgical treatment (two operations and double approach) was followed by radiotherapy and chemotherapy. The diagnosis is often made at a late stage, when neurological deficits produced by epidural compression become evident. The surgical treatment is only palliative but has several goals: obtaining a biopsy, improving the neurological symptoms through decompression, stabilizing and "rebuilding" the spinal column; it is performed using posterior, anterior or combined approaches which are discussed. The combined surgical, radiotherapeutic and polychemotherapeutic treatment is associated with a 5-year survival rate of 60-80%. Such a prognosis justifies the risk of surgery which will lead to a stable and lasting reconstruction. [less ▲]

Detailed reference viewed: 63 (1 ULg)
Full Text
Peer Reviewed
See detailLes lymphomes
Jerusalem, Guy ULg; Hustinx, Roland ULg; Beguin, Yves ULg et al

in Médecine Nucléaire : Imagerie Fonctionnelle et Métabolique (2003), 27(8), 401-410

Actuellement, on arrive à guérir 70-80% des patients atteints de maladie de Hodgkin et 50% des patients atteints de lymphome non-Hodgkinien de malignité intermédiaire ou élevée. Une approche systématique ... [more ▼]

Actuellement, on arrive à guérir 70-80% des patients atteints de maladie de Hodgkin et 50% des patients atteints de lymphome non-Hodgkinien de malignité intermédiaire ou élevée. Une approche systématique concernant le diagnostic, la classification de la maladie et la détermination des facteurs pronostiques permet de choisir la thérapeutique la plus appropriée. Les auteurs passent en revue les examens à réaliser au diagnostic et discutent de la place de la tomographie à émission de positons (TEP) dans cette indication. Ils évoquent ensuite le problème des masses résiduelles. La TEP est maintenant l'examen de choix pour établir le bilan de fin de traitement. Les auteurs discutent également du rôle potentiel de la TEP pour l'évaluation thérapeutique précoce et le suivi régulier des patients après traitement pour lymphome. Enfin, l'aspect particulier des lymphomes de l'enfant est abordé. [less ▲]

Detailed reference viewed: 43 (12 ULg)
Full Text
Peer Reviewed
See detailLymphotoxin alpha gene in Crohn's disease patients: absence of implication in the response to infliximab in a large cohort study
Dideberg, Vinciane ULg; Louis, Edouard ULg; Farnir, Frédéric ULg et al

in Pharmacogenetics and Genomics (2006), 16(5), 369-373

A haplotype in the lymphotoxin alpha (LTA) gene has been associated with a lack of response to infliximab in a small cohort of Crohn's disease (CD) patients. The present study aimed to confirm the ... [more ▼]

A haplotype in the lymphotoxin alpha (LTA) gene has been associated with a lack of response to infliximab in a small cohort of Crohn's disease (CD) patients. The present study aimed to confirm the implication of this haplotype in the response to infliximab in a larger cohort of Caucasian patients. The response to the first infusion with infliximab was evaluated in 214 Caucasian patients with either luminal (n = 150) or fistulising (n = 64) CD. Clinical response was based on the decrease in CID Activity Index (luminal) or on the evolution in the fistula discharge (fistulising). Biological response was assessed in 139 patients who had elevated C-reactive protein (CRP) before treatment and for whom CRP values were also available after treatment. A positive biological response was defined as a decrease in CRP of at least 25%. The patients were genotyped for six polymorphisms in the LTA gene. A positive clinical response was present in 65.4% of the patients and a positive biological response was observed in 80.6% of the patients. No association was found with any of the studied polymorphisms, nor with the previously published LTA haplotype and the response to infliximab. We could not confirm an association between the LTA locus and clinical or biological response to infliximab in a large cohort of CID patients. Pharmacogenetics and Genomics 16:369-373 (c) 2006 Lippincott Williams [less ▲]

Detailed reference viewed: 37 (1 ULg)
Full Text
Peer Reviewed
See detailThe lymphotoxin-beta receptor induces different patterns of gene expression via two NF-kappaB pathways.
Dejardin, Emmanuel ULg; Droin, Nathalie; Delhase, Mireille et al

in Immunity (2002), 17

The lymphotoxin-beta receptor (LTbetaR) plays critical roles in inflammation and lymphoid organogenesis through activation of NF-kappaB. In addition to activation of the classical NF-kappaB, ligation of ... [more ▼]

The lymphotoxin-beta receptor (LTbetaR) plays critical roles in inflammation and lymphoid organogenesis through activation of NF-kappaB. In addition to activation of the classical NF-kappaB, ligation of this receptor induces the processing of the cytosolic NF-kappaB2/p100 precursor to yield the mature p52 subunit, followed by translocation of p52 to the nucleus. This activation of NF-kappaB2 requires NIK and IKKalpha, while NEMO/IKKgamma is dispensable for p100 processing. IKKbeta-dependent activation of canonical NF-kappaB is required for the expression but not processing of p100 and for the expression of proinflammatory molecules including VCAM-1, MIP-1beta, and MIP-2 in response to LTbetaR ligation. In contrast, IKKalpha controls the induction by LTbetaR ligation of chemokines and cytokines involved in lymphoid organogenesis, including SLC, BLC, ELC, SDF1, and BAFF. [less ▲]

Detailed reference viewed: 7 (4 ULg)